Biocon - Global Healthcare Company
About Biocon Biocon's Products & Services Research & Development Biocon's Technology Investors Media Careers CSR
  Featured News
  Press Release
  Download Center
  Video Gallery
  Photo Gallery
  Media FAQs
  Media Contacts


  Latest News

<< Back
Biocon net profit down 4%...
October 21, 2011
Publication : Times of India
Bangalore: Biocon's net profit in the quarter ended September, 2011, dropped 4% to Rs 86 crore compared to the corresponding period in 2010-11. Last year's numbers include those of AxiCorp, Biocon's German subsidiary, which it sold earlier this year. Excluding AxiCorp, net profit rose 5%.

Biocon's revenue in the quarter rose 23% to Rs 524 crore.

Material, power and staff costs weighed down the net profit. Staff costs increased 38% to Rs 72 crore, and material and power costs increased 25% to Rs 237 crore.

"The company has seen a good performance in biopharmceuticals. But margins haven't improved even after the AxiCorp divestment," said Saurabh Jain, AVP-equities in SMC Global Securities. EBITDA margin was at 29%.

The biopharmaceuticals business grew 21% to Rs 415 crore, out of which branded formulations, including the diabetology and cardiology divisions, contributed Rs 64 crore, a 30% jump over the September quarter last year. The contract research business comprising of its contract research arm Syngene and clinical trial arm Clinigene posted a 19% growth to Rs 93 crore.

The net realization in licencing income for the first six months of the year dropped to Rs 11 crore, from Rs 44 crore in the corresponding period last year. Kiran Mazumdar-Shaw, CMD of Biocon, said the company had received $100 million from Pfizer as upfront licensing fee. "But we are only recognizing it as we progress development. At the gross level, licensing income grew to Rs 51 crore. But at a net level, because of development costs, we were only able to recognize Rs 11 crore at a PAT level. That makes a big difference to margins as well," she said.

Biocon and Pfizer have entered into a $350 million global agreement for the worldwide commercialization of Biocon's biosimilar versions of insulin and insulin analog products.

Biocon is continuing to discuss with global pharma companies on a partnership for its oral insulin candidate IN-105 and the Anti CD6 Mab programme for psoriasis.

The company said the phase III study in psoriasis will be completed in the first quarter of next year. The company launched a reusable insulin delivery device, Insupen, early this week based on proprietary German technology.
<< Back
  Related links:
    Product Glossary
    Financial Highlights
    Photo Gallery


Recommended sites Biocon on  
About Us

Investor Relations
Media Relations
Site Map
Contact Us
Our Growth Accelerators
Fact Sheet
Branded Formulations
Research Services
Active Discovery Program

Karnataka Vision Group on BT
Syngene International
Biocon Academy

    Linked In   
  Report adverse event/side effects and product complaints    
  * Disclaimer | Authorised Users               © 2015, Biocon. All Rights Reserved